Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx
NCT ID: NCT00002454
Last Updated: 2011-07-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
INTERVENTIONAL
1971-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Avelumab for People With Recurrent Respiratory Papillomatosis
NCT02859454
Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis
NCT00829608
Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)
NCT00001126
Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies
NCT02241369
A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis
NCT00038714
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks.
PROJECTED ACCRUAL: Not specified
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
autologous tumor cell vaccine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
PATIENT CHARACTERISTICS: Age: 1 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
PRIOR CONCURRENT THERAPY: See Disease Characteristics
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Medicine and Dentistry of New Jersey
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
James M. Oleske, MD
Role: STUDY_CHAIR
Rutgers, The State University of New Jersey
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New Jersey Medical School
Newark, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Oleske J, Fishman D, Cooper R, et al.: Autogenous vaccine in the treatment of laryngeal papilloma. In: Proceeding of the 12th International Congress of Chemotherapy, 1981. pp 1099-1101.
Oleske JM, Kushnick T. Juvenile papilloma of the larynx. Am J Dis Child. 1971 May;121(5):417-9. doi: 10.1001/archpedi.1971.02100160087011. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NJ-LAR-1
Identifier Type: -
Identifier Source: secondary_id
NJ-M-41-1976
Identifier Type: -
Identifier Source: secondary_id
CDR0000071657
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.